share_log

The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton's Partnered Epilepsy Drug, ASCO Conference Gets Underway And More

The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton's Partnered Epilepsy Drug, ASCO Conference Gets Underway And More

生物技術的未來一周(5 月 30 日至 6 月 4 日):FDA 決定伊頓合作的癲癇藥物,ASCO 會議正在進行等等
Benzinga Real-time News ·  2022/05/30 14:04
Biotech stocks advanced in the week ended May 27, tracking the overall positive sentiment of the broader market. Notwithstanding the week's strength, the sector has been one of the worst performers for the year-to-date period.
生物科技股在截至5月27日的一週內上漲,跟蹤了大盤的整體積極情緒。儘管本週表現強勁,但該板塊是今年迄今表現最差的板塊之一。
Among notable developments, Genocea Biosciences, Inc. (NASDAQ:GNCA) announced that it is shuttering operations amid a cash crunch. The company also plans to voluntarily delist its shares from Nasdaq by June 2.
在值得注意的事態發展中,Genocea Biosciences,Inc.納斯達克(Sequoia Capital:GNCA)宣佈,在資金緊張的情況下,將停止運營。該公司還計劃在6月2日前自願將其股票從納斯達克退市。
Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA) suffered a setback after its viral skin infection treatment candidate was rejected by the Food and Drug Administration on its third try.
Verrica製藥公司。納斯達克:VRCA)遭遇挫折,其首個病毒性皮膚感染治療候選藥物在第三次嘗試時被美國食品和藥物管理局拒絕。
Catalyst Biosciences, Inc. (NASDAQ:CBIO...
Catal...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論